Riemser Pharma

Could a pharmaceutical giant rise from a tiny island? Here at Riemser Pharma in Greifswald, the answer is a resounding yes. Riemser Pharma’s story began in 1992, emerging from the Friedrich Löffler Institute on Riems Island. This wasn’t just any location. It was a place already steeped in veterinary research. Riemser Pharma’s journey is a fascinating transformation. It evolved from its veterinary roots into a key player in specialty pharmaceuticals for human medicine. Riemser Pharma doesn’t just manufacture. They acquire, license, market, and distribute, navigating the complex world of pharmaceuticals with expertise. Their focus is on niche therapeutic areas. These include oncology, infectiology, neurology, cardiovascular medicine, dermatology, rheumatology, and even treatments for obesity and hyperhidrosis. Riemser Pharma’s reach extends globally with over 400 approvals worldwide. A remarkable 28 of these approvals were secured in just the last three years. This demonstrates their proficiency in navigating the regulatory landscape. The company’s headquarters are in Berlin. They have locations throughout Germany, and subsidiaries in France (Keocyt) and England (Intrapharm), acquired in 2014 and 2015, respectively. Riemser Pharma even made inroads into the Spanish market by acquiring distribution service provider Zaltanpharma in 2019, renaming it Riemser Iberia. Backing this impressive growth is Ardian, a world-leading private investment company. Then, in 2020, Esteve, a Barcelona-based international pharmaceutical company, acquired Riemser Pharma, marking a new chapter in its evolution. This acquisition aimed to bolster Esteve’s presence in the hospital market, a sector where Riemser Pharma excels. Interestingly, about 80% of Riemser Pharma’s sales come from products for clinical application, demonstrating their strong foothold in this market. Their drugs are so effective that many are even considered the “gold standard” in their respective fields. Riemser Pharma’s story is a testament to the power of transformation and strategic growth. From a small island beginning to a global pharmaceutical force, their journey continues to inspire.